NASDAQ:AXGN - AxoGen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.75
  • Forecasted Upside: 10.88 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$21.42
▼ -0.19 (-0.88%)
1 month | 3 months | 12 months
Get New AxoGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXGN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$23.75
▲ +10.88% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for AxoGen in the last 3 months. The average price target is $23.75, with a high forecast of $27.00 and a low forecast of $21.00. The average price target represents a 10.88% upside from the last price of $21.42.
Buy
The current consensus among 5 polled investment analysts is to buy stock in AxoGen. This rating has held steady since August 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021SVB LeerinkBoost Price TargetOutperform$23.00 ➝ $27.00Low
i
3/1/2021Canaccord GenuityBoost Price TargetHold$20.00 ➝ $21.00Low
i
2/23/2021Canaccord GenuityBoost Price TargetHold$20.00 ➝ $21.00High
i
2/23/2021SVB LeerinkBoost Price TargetOutperform$23.00 ➝ $27.00Medium
i
1/12/2021Cantor FitzgeraldBoost Price TargetOverweight$16.00 ➝ $23.00High
i
10/22/2020GuggenheimInitiated CoverageBuy$24.00Low
i
9/16/2020Canaccord GenuityReiterated RatingHold$13.00High
i
Rating by Kyle Rose at Canaccord Genuity
8/6/2020SVB LeerinkBoost Price TargetOutperform$13.50 ➝ $15.50High
i
8/5/2020BTIG ResearchReiterated RatingHoldHigh
i
Rating by Ryan Zimmerman at BTIG Research
7/1/2020Canaccord GenuityDowngradeHold$12.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
7/1/2020BTIG ResearchDowngradeHoldHigh
i
Rating by Ryan Zimmerman at BTIG Research
6/15/2020Cantor FitzgeraldInitiated CoverageBuy$16.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
6/8/2020Cantor FitzgeraldReiterated RatingOverweightLow
i
Rating by B. Folkes at Cantor Fitzgerald
5/7/2020Canaccord GenuityDowngradeBuy ➝ Hold$12.00High
i
4/2/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
i
2/25/2020Canaccord GenuityReiterated RatingBuy$22.00High
i
12/16/2019BTIG ResearchReiterated RatingBuy$21.00High
i
8/7/2019Canaccord GenuitySet Price TargetBuy$30.00Medium
i
Rating by Kyle Rose at Canaccord Genuity
8/7/2019JMP SecuritiesLower Price TargetOutperform$43.00 ➝ $28.00Medium
i
8/7/2019BTIG ResearchLower Price TargetBuy$21.00High
i
8/7/2019William BlairDowngradeOutperform ➝ Market PerformHigh
i
Rating by B. Weinstein at William Blair
8/7/2019Cantor FitzgeraldLower Price TargetOverweight$30.00 ➝ $21.00High
i
Rating by Craig Bijou at Cantor Fitzgerald
7/12/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$32.00High
i
5/10/2019BTIG ResearchReiterated RatingBuy$29.00Medium
i
5/9/2019Cantor FitzgeraldReiterated RatingOverweight$26.00 ➝ $30.00High
i
Rating by Craig Bijou at Cantor Fitzgerald
4/22/2019Cantor FitzgeraldSet Price TargetBuy$26.00Low
i
Rating by Craig Bijou at Cantor Fitzgerald
3/25/2019BTIG ResearchUpgradeNeutral ➝ Buy$28.00High
i
1/18/2019Cantor FitzgeraldSet Price TargetBuy$26.00Low
i
Rating by Craig Bijou at Cantor Fitzgerald
12/19/2018Cantor FitzgeraldReiterated RatingBuy$43.00High
i
11/14/2018BTIG ResearchInitiated CoverageNeutralHigh
i
10/30/2018Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$45.00 ➝ $43.00Medium
i
10/30/2018SVB LeerinkReiterated RatingOutperform$55.00High
i
8/9/2018Cantor FitzgeraldReiterated RatingBuy$45.00Low
i
6/26/2018SVB LeerinkReiterated RatingOutperform$70.00High
i
5/1/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Market Outperform$34.00 ➝ $43.00High
i
5/1/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$37.00 ➝ $45.00High
i
Rating by Craig Bijou at Cantor Fitzgerald
3/19/2018Jefferies Financial GroupBoost Price TargetBuy$45.00Medium
i
3/2/2018Lake Street CapitalSet Price TargetBuy ➝ Buy$26.00 ➝ $38.00Medium
i
Rating by Bruce Jackson at Lake Street Capital
3/1/2018JMP SecuritiesBoost Price TargetMarket Outperform$27.00 ➝ $34.00High
i
2/5/2018William BlairInitiated CoverageOutperformHigh
i
Rating by K. Krum at William Blair
1/8/2018Cantor FitzgeraldSet Price TargetBuy$37.00High
i
Rating by Craig Bijou at Cantor Fitzgerald
1/5/2018Cantor FitzgeraldReiterated RatingOverweight ➝ OverweightHigh
i
Rating by Travis Steed at Cantor Fitzgerald
11/30/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$35.00High
i
11/21/2017SVB LeerinkBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $30.00N/A
i
11/21/2017Lake Street CapitalBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.00N/A
i
11/21/2017WedbushReiterated RatingBuy$22.00 ➝ $27.00N/A
i
11/2/2017SVB LeerinkBoost Price TargetOutperform$23.00 ➝ $26.00N/A
i
9/30/2017SVB LeerinkReiterated RatingOutperform$22.00 ➝ $23.00Medium
i
9/12/2017Roth CapitalReiterated RatingBuy$18.00 ➝ $21.00Low
i
8/21/2017Cantor FitzgeraldReiterated RatingBuy$18.00Low
i
7/31/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$22.00High
i
6/29/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$18.00High
i
5/19/2017WedbushReiterated RatingOutperform$17.00 ➝ $14.00High
i
3/6/2017Roth CapitalInitiated CoverageBuy ➝ Buy$14.50N/A
i
Rating by C. Lewis at Roth Capital
1/10/2017WedbushReiterated RatingOutperform$12.00N/A
i
11/25/2016WedbushReiterated RatingOutperform$12.00N/A
i
11/22/2016JMP SecuritiesReiterated RatingBuyN/A
i
11/22/2016Lake Street CapitalUpgradeHold ➝ Buy$9.00 ➝ $11.00N/A
i
Rating by B. Jackson at Lake Street Capital
11/7/2016WedbushBoost Price TargetOutperform$10.00 ➝ $12.00N/A
i
11/3/2016Lake Street CapitalDowngradeBuy ➝ Hold$9.00N/A
i
Rating by B. Jackson at Lake Street Capital
8/4/2016WedbushReiterated RatingOutperform$9.00 ➝ $10.00N/A
i
5/5/2016WedbushReiterated RatingOutperform$7.50N/A
i
(Data available from 3/4/2016 forward)
AxoGen logo
AxoGen, Inc., together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Read More

Today's Range

Now: $21.42
$21.38
$21.56

50 Day Range

MA: $19.55
$17.18
$22.60

52 Week Range

Now: $21.42
$7.16
$22.89

Volume

184 shs

Average Volume

267,858 shs

Market Capitalization

$870.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Frequently Asked Questions

What sell-side analysts currently cover shares of AxoGen?

The following Wall Street research analysts have issued reports on AxoGen in the last twelve months: BTIG Research, Canaccord Genuity, Cantor Fitzgerald, Guggenheim, and SVB Leerink LLC.
View the latest analyst ratings for AXGN.

What is the current price target for AxoGen?

4 Wall Street analysts have set twelve-month price targets for AxoGen in the last year. Their average twelve-month price target is $23.75, suggesting a possible upside of 6.9%. SVB Leerink LLC has the highest price target set, predicting AXGN will reach $27.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $21.00 for AxoGen in the next year.
View the latest price targets for AXGN.

What is the current consensus analyst rating for AxoGen?

AxoGen currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AXGN will outperform the market and that investors should add to their positions of AxoGen.
View the latest ratings for AXGN.

What other companies compete with AxoGen?

How do I contact AxoGen's investor relations team?

AxoGen's physical mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider's listed phone number is 386-462-6800 and its investor relations email address is [email protected] The official website for AxoGen is www.axogeninc.com.